Back to Screener

Kenvue Inc. (KVUE)

Price$17.71
Value ScoreC
Growth ScoreC
Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-5.85%
Price vs S&P 500 (4W)0.69%
VGM Score53.11
Market Capitalization$34.00B
P/E Ratio (Annual)23.13x
Indicated Dividend Yield (Annual)4.92%

All Metrics

P/CF (Annual)15.48x
Book Value / Share (Quarterly)$5.53
P/TBV (Annual)15.90x
Indicated Dividend (Annual)$0.83
Revenue Growth (3Y)0.39%
Cash Flow / Share (Quarterly)$0.95
Payout Ratio (TTM)97.84%
Price vs S&P 500 (YTD)-5.49%
Gross Margin (TTM)58.85%
Net Profit Margin (TTM)10.61%
EPS (TTM)$0.84
10-Day Avg Trading Volume22.53M
EPS Excl Extra (TTM)$0.84
Revenue Growth (5Y)0.89%
EPS (Annual)$0.76
Dividend / Share (Annual)$0.83
ROI (Annual)7.62%
Gross Margin (Annual)58.62%
Net Profit Margin (5Y Avg)10.92%
Cash / Share (Quarterly)$0.56
P/E Basic Excl Extra (TTM)20.96x
Revenue Growth QoQ (YoY)4.49%
P/E Normalized (Annual)23.13x
ROA (Last FY)5.43%
Revenue Growth TTM (YoY)-0.07%
EBITD / Share (TTM)$1.66
ROE (5Y Avg)11.91%
Operating Margin (TTM)17.15%
Cash Flow / Share (Annual)$0.90
P/B Ratio3.21x
P/B Ratio (Quarterly)3.12x
Net Income / Employee (Annual)$67,500
EV / Revenue (TTM)2.72x
Net Interest Coverage (TTM)5.70x
ROA (TTM)5.99%
EPS Growth QoQ (YoY)47.40%
EV / EBITDA (TTM)13.05x
EPS Incl Extra (Annual)$0.76
Current Ratio (Annual)0.96x
Quick Ratio (Quarterly)0.63x
3-Month Avg Trading Volume28.81M
52-Week Price Return-18.20%
EV / Free Cash Flow (Annual)24.15x
P/E Incl Extra (TTM)20.96x
Revenue / Employee (TTM)$702,100
Tangible BV / Share (Quarterly)$1.08
P/S Ratio (Annual)2.25x
Asset Turnover (Annual)0.56x
52-Week High$22.87
Operating Margin (5Y Avg)16.32%
EPS Excl Extra (Annual)$0.76
CapEx CAGR (5Y)15.71%
26-Week Price Return2.07%
Quick Ratio (Annual)0.61x
13-Week Price Return-2.96%
Total Debt / Equity (Annual)0.79x
Current Ratio (Quarterly)0.98x
Enterprise Value$41.59B
Revenue / Share Growth (5Y)0.52%
Asset Turnover (TTM)0.56x
Revenue / Employee (Annual)$694,400
Inventory Turnover (Annual)3.84x
Pretax Margin (Annual)13.22%
Cash / Share (Annual)$0.55
3-Month Return Std Dev21.56%
Gross Margin (5Y Avg)57.11%
Net Income / Employee (TTM)$74,500
ROE (Last FY)13.66%
Net Interest Coverage (Annual)6.56x
EPS Basic Excl Extra (Annual)$0.76
P/FCF (TTM)18.65x
Receivables Turnover (TTM)6.35x
EV / Free Cash Flow (TTM)22.81x
Total Debt / Equity (Quarterly)0.82x
EPS Incl Extra (TTM)$0.84
Receivables Turnover (Annual)6.65x
ROI (TTM)8.37%
P/S Ratio (TTM)2.22x
Pretax Margin (5Y Avg)14.73%
Revenue / Share (Annual)$7.86
Tangible BV / Share (Annual)$1.08
Forward P/E14.15x
Free OCF CAGR (5Y)-11.48%
Price vs S&P 500 (52W)-42.56%
P/E Ratio (TTM)20.96x
EPS Growth TTM (YoY)53.73%
Year-to-Date Return2.67%
5-Day Price Return2.07%
EPS Normalized (Annual)$0.76
ROA (5Y Avg)6.07%
Net Profit Margin (Annual)9.72%
Month-to-Date Return2.49%
EBITD / Share (Annual)$1.54
EPS Growth (3Y)-11.57%
Operating Margin (Annual)15.96%
LT Debt / Equity (Annual)0.64x
P/CF (TTM)15.06x
ROI (5Y Avg)8.43%
P/E Excl Extra (TTM)20.96x
LT Debt / Equity (Quarterly)0.67x
EPS Basic Excl Extra (TTM)$0.84
P/TBV (Quarterly)16.01x
Payout Ratio (Annual)107.55%
P/B Ratio (Annual)3.06x
Dividend / Share (TTM)$0.83
Inventory Turnover (TTM)3.75x
Pretax Margin (TTM)14.47%
Book Value / Share (Annual)$5.62
Price vs S&P 500 (13W)-11.21%
Dividend Yield (TTM)4.67%
Beta0.49x
P/FCF (Annual)19.75x
Revenue / Share (TTM)$7.96
ROE (TTM)15.18%
52-Week Low$14.02
vGradeC
gGradeC
mGradeC
vgmGradeC
Show chart for

Earnings Surprise History

Q1 260.32est. 0.27

Analyst Recommendations

Mar 2026
Apr 2026
May 2026
Jun 2026
2.75
2.75
2.75
2.72

About

Kenvue is the world's largest pure-play consumer health company with over $15 billion in annual revenue, offering products across pain management, oral care, cough and cold care, and skincare through iconic brands including Tylenol, Listerine, Aveeno, and Neutrogena. Spun off from Johnson & Johnson in May 2023, the company agreed to be acquired by Kimberly-Clark in November 2025, with the transaction expected to close in the second half of 2026.